Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Daito Pharmaceutical Co., Ltd. ( (JP:4577) ) has issued an update.
Daito Pharmaceutical Co., Ltd. announced its decision to acquire and subsequently cancel a significant portion of its treasury shares as part of its capital policy under the Medium-Term Management Plan. This move aims to enhance shareholder returns and improve capital efficiency, with up to 1,250,000 shares, representing 4.2% of the total shares issued, set to be acquired and cancelled. The acquisition will be conducted through the Tokyo Stock Exchange, with the cancellation scheduled for May 2026.
The most recent analyst rating on (JP:4577) stock is a Hold with a Yen1261.00 price target. To see the full list of analyst forecasts on Daito Pharmaceutical Co., Ltd. stock, see the JP:4577 Stock Forecast page.
More about Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and distribution of pharmaceutical products. The company is listed on the Prime Market of the Tokyo Stock Exchange.
Average Trading Volume: 72,427
Technical Sentiment Signal: Buy
Current Market Cap: Yen35.93B
See more insights into 4577 stock on TipRanks’ Stock Analysis page.